MegaPro Biomedical Co. Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Taipei Taiwan (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2016
NCT02744248
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

MegaPro Biomedical Co. Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

iron oxide (3 trials)

mpb-1734 (1 trial)

Drugs in Phase 1 Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Anemia, Iron-Deficiency (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3